POXEL和ENYO制药为POXEL的FXR激动剂计划注册许可协议 法国里昂

StephenW

POXEL and ENYO Pharma Sign License Agreement for POXEL’s FXR Agonist Program
LYON, France, May 06, 2015 (BUSINESS WIRE) -- POXEL SA (POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, and ENYO Pharma SAS, a newly-formed company focused on the treatment of acute and chronic viral infections, today announced the signing of a license agreement under which ENYO will gain access to Poxel’s FXR (farnesoid X receptor) agonist compounds for infection-related indications with Poxel retaining rights for cardiovascular and metabolic indications among others. No financial terms of the agreement have been disclosed.

“Poxel has advanced its pipeline based on both our internal expertise in metabolism and cellular bioenergetics and the clinical and preclinical programs we inherited as a spin-out from Merck Serono,” said Thomas Kuhn, CEO of Poxel. “The breadth of therapeutic applications and opportunities represented in this pipeline allows us to out-license compounds for indications outside of our therapeutic focus, thereby bringing in additional revenues and broadening our network of partners.”

“We had opportunity to collaborate with the team at Poxel as an academic research group prior to our founding as a company and are very excited to gain access to Poxel’s FXR agonist program for our further developments in the area of liver-based infections,” commented Jacky Vonderscher, PhD, President of ENYO. “Our goal is to rapidly conduct all IND-enabling studies in order to bring the lead compound into Phase 1 during Q1 2016 and subsequently to treat chronic hepatitis B patients in Phase 2 by 2017.”

About FXR

Farnesoid X receptor (FXR), also known as bile acid receptor, is a member of a nuclear receptor superfamily and has a role in multiple metabolic pathways and especially in controlling the fate of bile acids in the liver and the intestine. It has also been reported to influence insulin sensitivity of these tissues where it is expressed at high levels. The Inserm team founder of ENYO has identified FXR as a direct regulator of hepatitis B virus replication and has shown the dependency of the virus life cycle on the bile acids pathway. Modulating FXR becomes therefore a promising new therapeutic avenue to control and potentially cure chronic hepatitis B which is one of the world leading causes of cirrhosis and liver cancer.

About Poxel SA

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

About ENYO Pharma SAS

ENYO Pharma was founded in 2014 by four scientists from the International Center for Research in Infectiology, Inserm U1111 in Lyon, France, and seeding partners (Inserm Transfert Initiative, ADV Life Sciences and Vonderscher & Co) followed earlier this year by Sofinnova Partners, a leading venture capital firm based in Paris. The mission of ENYO Pharma is to develop molecules targeting specific host functions for the treatment of acute and chronic viral infections. ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules modulating them. The company is currently hosted by Inserm in the Infectiology Center of Lyonbiopôle in Lyon, and maintains tight collaborations with the seminal Inserm team and several international academic groups. (www.enyopharma.com)

SOURCE: POXEL SA

Media Contacts
For Poxel SA
Pascale Malgouyres, +33 437 372 012
Chief Business Officer
[email protected]
or
Gretchen L. P. Schweitzer, Direct: +49 89 2424 3495
Mobile : +49 172 861 85
[email protected]
or
Nicolas Merigeau (Media Relations, France)
Florent Alba (Investor Relations, France)
Direct +33 1 44 71 98 55
[email protected]
or
For ENYO Pharma SAS:
Jacky Vonderscher, +33 437 262 976
President
[email protected]

Copyright Business Wire 2015

StephenW

POXEL和ENYO制药为POXEL的FXR激动剂计划注册许可协议
法国里昂，2015年5月6日（美国商业资讯） - POXEL SA（POXEL），一家生物制药公司开发创新药物治疗2型糖尿病，ENYO制药SAS，一个新成立的公司，专注于急性和慢性治疗病毒感染，今天宣布了一项许可协议，根据协议ENYO将获得Poxel的FXR（法尼醇X受体）激动剂化合物为感染相关的适应症Poxel保留了在其他心血管疾病和代谢迹象权利的签字仪式。该协议的任何财务条款已经被公开。

“Poxel拥有先进的流水线基础上，代谢和细胞生物能量，我们继承了一个旋，从默克雪兰诺的临床和临床前两种方案我们内部的专业知识，”托马斯·库恩，Poxel的首席执行官说。 “治疗应用和机会在这条管道为代表的广度让我们来出牌化合物适应症的治疗我们外焦，从而带来额外的收入，并扩大我们的合作伙伴网络。”

“我们有机会在Poxel与团队合作，因为之前我们成立一个公司一个学术调研组很高兴获得Poxel的FXR激动剂方案为我们的肝脏为主的感染区域的进一步发展，”评论张学友Vonderscher，博士，ENYO主席。 “我们的目标是迅速开展以2016年第一季度带来的先导化合物进入第一阶段的所有IND-使研究和随后治疗慢性乙型肝炎患者的2期2017年”

关于FXR

法尼酯X受体（FXR），也被称为胆汁酸受体，是核受体超家族的成员，并具有多个代谢途径，特别是在控制在肝脏和肠的胆汁酸的命运的作用。还已经报道影响这些组织在那里以高水平表达的胰岛素敏感性。 ENYO的INSERM创始人团队已经确定FXR作为乙肝病毒复制的直接监管机构，并表现出这种病毒的生命周期的胆汁酸途径的依赖。因此，调节FXR成为一个充满希望的新的治疗途径来控制和治疗潜在的慢性乙型肝炎是世界领先的肝硬化和肝癌的原因之一。

关于Poxel SA

Poxel利用其独特的发展专长代谢推进目前主要集中在2型糖尿病的真正新颖的产品流水线。我们以一流的产品铅，Imeglimin，针对线粒体功能障碍，已成功地完成了第2阶段的发展，在美国和欧盟，并已进入临床开发在日本。我们正在推进我们的第二个项目，PXL770，直接AMPK激活，通过临床验证的概念。我们将通过生成战略伙伴关系和管道的发展进一步增长。 （泛欧证券交易所：POXEL，www.poxel.com）

关于ENYO制药SAS

ENYO制药成立于2014年由国际研究中心Infectiology，INSERM U1111在里昂，法国4名科学家，播种伙伴（INSERM Transfert倡议，ADV生命科学和Vonderscher＆CO。），随后在今年早些时候由Sofinnova的合作伙伴，一个领先的总部设在巴黎的风险投资公司。 ENYO制药的使命是开发针对特定主机功能的急性和慢性病毒感染的治疗分子。 ENYO制药已授权从创始科学家的发现发布了若干INSERM专利和开发了一个独特的平台，为细胞内的治疗靶点和分子调节他们的身份。该公司目前由INSERM在Lyonbiopôle在里昂Infectiology中心主办，并保持紧密的合作与精液INSERM的团队和多个国际学术团体。 （www.enyopharma.com）

来源：POXEL SA

媒体联系
对于Poxel SA
帕斯卡尔Malgouyres，+33 437 372 012
首席商务官
[email protected]
或
格雷琴LP史怀哲，直接：+49 89 2424 3495
手机：+49 172 861 85
[email protected]
或
萨科Merigeau（媒体关系，法国）
弗洛朗·奥尔芭（投资者关系，法国）
直接+33 1 44 71 98 55
[email protected]
或
对于ENYO制药SAS：
张学友Vonderscher，+33 437 262 976
总统
[email protected]

版权所有美国商业资讯2015年